Thrombopoietin (TPO) is a newly identified hematopoietic growth factor that stimulates both megakaryopoiesis and thrombopoiesis through its interaction with a specific cell surface receptor encoded by the c-mpl proto-oncogene. In an effort to investigate the effect of TPO on human myeloid leukemia cells, the expression of c-mpl and the proliferative response to recombinant human (rhj TPO were investigated in a series of patients with acute myeloblastic leukemia (AML). Of 50 cases of AML, the c-mpl mRNA was detectable by means of Northern blot analysis in 26 cases, and the in vitro treatment with rhTPO led t o proliferation of AML cells in 22 cases. The c-mpl expression and proliferative response to rhTPO was observed in all subtypes of AML and did
T HE c-mpl PROTO-ONCOGENE was originally identified as the cellular homologue of the oncogene v-mpl transduced in the myeloproliferative leukemia retrovirus that induces a broad spectrum of mammalian The c-mpl proto-oncogene encodes a transmembrane receptor that is a member of hematopoietin receptor superfamily with high sequence similarity to the receptors for erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF)."-7 It has been reported that c-mpl is expressed exclusively on hematopoietic tissues, particularly on CD34' hematopoietic stem cells, megakaryocytes, and platelets, although a low level of c-mpl expression is also detectable on endothelial cells.". ' The treatment of CD34+ cells with antisense oligodeoxynucleotides to c-mpl mRNA has been shown to result in selective inhibition of in vitro megakaryocytic colony formation without affecting the growth of erythroid or granulomacrophage colonies.' These results suggested that putative c-mpl ligand may play a crucial role in megakaryopoiesis.
Recently, several groups of investigators have purified and cloned the rnpl ligand that has NH,-terminal domain homologous to EPO and COOH-terminal domain unrelated to any known pr~tein.'"~ The in vitro and in vivo studies have shown that the mpl ligand has activity in stimulating both megakaryopoiesis and platelet production. Also, Kat0 from the plasma of irradiated rats by measuring its activity on in vitro megakaryocyte production. They have subsequently cloned the genes for rat and human thrombopoietic factors and have shown them to have sequence identity to the mpl ligand.I4.l5 Thus, the mpl ligand is now shown to be the longsought platelet growth factor, thrombopoietin (m) itself.
The proliferation and maturation of normal hematopoietic cells are positively or negatively regulated by a variety of hematopoietic growth factors. In addition to normal hematopoietic cells, proliferation of acute myeloblastic leukemia (AML) cells in vitro can be stimulated in most cases by one or more hematopoietic growth factors such as interleukin-3 (K-3), K-6, stem cell factor (SCF), and granulocyte-macrophage colony-stimulating factor (GM-CSF). [16] [17] [18] [19] [20] [21] [22] Furthermore, a number of studies have suggested that disregulated et al14. 15 expression of hematopoietic growth factors and/or their receptors could be involved in some aspect of excessive proliferation and aberrant differentiation of leukemia It is therefore important to clarify the role of hematopoietic growth factors and their receptors in growth of AML cells not only for a better understanding of mechanisms underlying abnormal growth of AML cells but also for evaluating therapeutic procedure of the factors in patients with AML. However, in the case of c-mpl, the functional role of c-mpl in AML cells is not known, although c-mpl expression has previously been reported to be detected in about half the number of patients with AML.2' In this study, we therefore examined the expression of c-mpl in a series of AML cases and investigated the effects of recombinant human TPO (rhTPO) on proliferation of AML cells with or without combination with other hematopoietic growth factors. Cell lines. M07E, a human GM-CSF-, SCF-, IL-2-, and IL-3-dependent cell line,29,30 was obtained from Dr Steven Clark (Genetics   Institute, Cambridge, MA) and was originally established by Avanzi  et aI2' from the peripheral blood of an infant with an acute megakaryocytic leukemia. TF-l, a human GM-CSF-and 1L-3-dependent cell line that was established from the peripheral blood of a patient with erythroleukemia, was kindly provided by Dr T. E t amura (DNAX Research Institute, Palo Alto, CA).?' M07E and TF-1 were cultured in RPMI 1640 medium (Nakarai Tesque, Kyoto, Japan) supplemented with 10% fetal calf serum (FCS; Flow, North Ryde, Australia) and 10 ng/mL of rhGM-CSF at 37°C. HMC-I , a human mast cell line established by Butterfield et aI3> was cultured in RPMI 1640 medium supplemented with 10% FCS. KU812-F (a human chronic myelogenous leukemia cell line), HEL (a human erythroleukemia cell line), K562 (a human chronic myelogenous leukemia cell line), THP-I (a human monocytic leukemia cell line), KG1 (a human myeloblastic leukemia cell line), HL-60 (a human promyelocytic leukemia cell line), and U937 (a human monocytic leukemia cell line) were obtained from the Japanese Cancer Research Bank (Tokyo, Japan) and were adapted to grow and maintained in RPMI 1640 supplemented with 10% FCS.
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Patients and leukemic cells. Peripheral blood or bone marrow samples were obtained from 50 patients with AML and 5 patients with acute lymphoblastic leukemia (ALL). All samples were obtained after informed consent was given. The diagnosis of leukemia was made by morphologic, cytochemical, and immunologic analyses, and each case was classified according to French-AmericanBritish (FAB) riter ria.'"^^ Three cases were classified as FAB MO, 6 as MI, 9 as M2,6 as M3, 8 as M4, IO as M5,4 as M6, and 4 as M7. Mononuclear cells were isolated with Ficoll-Hypaque (Nycomed Pharma AS, Oslo, Norway) density gradient centrifugation and cryopreserved in 10% dimethylsulfoxide in the vapor phase of liquid nitrogen until use. Samples used in this study contained greater than 90% leukemia cells and had a viability greater than 90% after thawing.
Cell proliferation assay. The frozen cells were thawed, washed, and suspended in RPMI 1640 medium supplemented with 10% FCS. The cells of each cell line were washed and suspended in serumfree Cos medium (Cosmo Bio, Tokyo, Japan). To quantitate the proliferation of cells, MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] (Sigma, St Louis, MO) rapid colorimetric assay was used as previously reported." In brief, triplicate aliquots of cells (3.0 X IO4 cells resuspended in 100 pL RPMI 1640 supplemented with 10% FCS or Cos medium) were cultured in 96-well flat-bottom microtiter plates for 72 hours at 37°C in the presence or absence of the growth factor(s). In some experiments, cells were cultured with various concentrations of rhTPO (0 to 100 ng/rnL) but in most experiments cells were treated with 20 ng/mL rhTPO, because this concentration of rhTP0 induced almost maximal proliferation of human leukemia cells. The concentrations of other growth factor were as follows: rhSCF, 100 ng/mL; rhIL-2, 50 nglmL; rhIL-3, 10 ng/mL; rhIL-6, 50 nglmL; rhGM-CSF, 10 ng/mL; and rhEPO, I O U/mL. MTT (10 pL of 5 mg/mL solution in PBS) was added for the final 4 hours of culture, and 100 pL of acid isopropanol (0.04 N HCI in isopropanol) was added to all wells and mixed. The optical density (OD) was then measured on the Microelisa plate reader (Corona Electric, Ibaragi, Japan) with a test wavelength of 540 nm and a reference wavelength of 620 nm. This assay was found to give equivalent results obtained by 'H-thymidine incorporation or cell enumeration as described previ~usly.~"."
Detection of c-mpl mRNA by Northern blot and reverse transcriptase-polymerase chain reaction (RT-PCR) analysis. Total cellular RNA was isolated with a guanidine isocyanate procedure. For RT-PCR, 2.5 pg of total cellular RNA was reverse-transcribed at 37°C for 60 minutes in a final volume of 50 pL with 200 U of Moloney leukemia virus reverse transcriptase (GIBCO BRL, Gaithersburg, MD), 2 pL of oligo dT primers (2 pmol/L), IO mrnoln dithiotereitol, 50 U of RNAsin (Toyobo, Osaka, Japan), and 1 mmoV L of dNTP mix using the reaction buffer provided by the manufacturer. The cDNA product (1.5 pL) was resuspended in a total volume of 15 pL containing 0.375 U of Taq DNA polymerase (Promega, Madison, WI), 2 mmol/L MgCIZ, 200 pmoVL dNTP mix, 15 pmol of forward and reverse primers, and I X reaction buffer provided by the manufacturer. To amplify two forms (K and P forms) of c-mpl cDNA, we used sense primer (5'-TGGCTGCAGCTGCGCAGC-GAACCT-3', nucleotides 757 to 780) in combination with 3K reverse primer (5'-TTAGAGTGTAAGGAGCCGCGGCGA-3', nucleotides 1717 to 1740) and 3P reverse primer (5"TCAAGG-CTGCTGCCAATAGCTTAG-3', nucleotides 1885 to 1908), respectively. 5C (5'-ATGCCCTCCTGGGCCCTCTTCATGG-3', nucleotides I to 25) and 3C (5'-TTGCAGTCCAAGTGCCACTG-CATC-3', nucleotides 847 to 870) primers were used to obtain the fragment included by both forms of c-mpl. The samples were denatured for 5 minutes at 94°C. followed by 30 cycles of amplification (94°C for 30 seconds for denaturation; 50°C for 30 seconds for annealing; and 72°C for 90 seconds for extension. Alliquots ( I O pL) were resolved on 1.5% agarose gels containing ethidium bromide to examine the existence and size of PCR products. PCR fragments were subcloned into Blue Script I1 SK( +) (Stratagene, San Diego), and sequence analysis was performed by dideoxynucleotide terminal method to confirm that the correct sequence of c-mpl were amplified. For Northem blot analysis, equal amounts of RNA (15 pg) were size-fractionated by electropheresis through 1 .O% formaldehyde agarose gels. After blotting to the nylon membranes, the filters were prehybridized and then hybridized with random "P-labeled probe in rapid hybridization buffer (Americiam, Tokyo, Japan) for 3 hours at 65°C. The probe was 170 bp of Sph I-NCO I fragment corresponding to nucleotides 253 through 423 of c-mpl cDNA obtained from the PCR product, which were common with both the P form and the K form. P-Actin probe was purchased from Nippon Gene (Toyanla, Japan). The filters were washed and autoradiographed at -70°C with two intensifying screens for 1 to 7 days.
RESULTS
Expression o j c-mpl transcripts in human leukemia cells. Expression of c-mpl mRNA was examined by means of Northern blot analysis in a series of AML in addition to ALL and various types of human leukemia cell lines. In accord with the previous findings on human leukemia cell lines, c-mpl transcripts were detected in TF-I, M07E, and HEL cells as a major 3.7-kb mRNA (P form) and a minor 2.8-kb (K form) (Fig l) . Little or no expression of c-mpl mRNA was observed in KG-l, HL-60, K562, THP-l, KU812-F, U937, or HMC-l cells by Northern blot analysis (Fig I) . In AML cells, expression of c-mpl mRNA were detectable in 26 of 50 cases (Fig 1 and Tables 1 and 2) . The c-mpl transcript in AML cells was expressed predominantly as the P form, and in most cases the K-form transcript was detectable only after long-term exposure. As shown in the representative Northern blots in Fig  1, furthermore, it was noted that, despite a considerable patient-to-patient variation in intensity of c-mpl transcripts, the expression levels of crnpl in AML cells were generally lower than those in TF-l , M07E. and HEL cells with the exception of some AML cases.
With regard to FAB type, mRNA of c-mpl were present in 2 of 3 M0 cases, 3 of 6 M1 cases, 7 of 9 M2 cases, 2 of (Table 2) . By contrast, c-mpl was not detected in any of ALL cases (Table 2) . Thus, crnpl transcripts were not limited to the specific types of AML, and there was no significant correlation between c-mpl expression and FAB classification. However, c-mpl expression was observed with high frequency in M7 type.
In addition to Northern blot analysis, we examined the expression of c-mpl using RT-PCR. Despite little message detected by Northern blot analysis in a substantial fraction of AML cases, RT-PCR analysis showed that both forms of c-mpl transcripts were noticeable in all cases of AML (data not shown). Furthermore, both forms of transcripts were amplified in KU812-F and HMC-I cells, but not in KG-l, HL-60, K562, THP-l, or U937 cells (data not shown).
Proliferative response of human leukemia cell lines to rhTP0. To determine whether rhTP0 induced proliferation of human leukemia cells, we first examined the dose-dependent effects of rhTPO on two human leukemia cell lines, M07E and TF-I, both of which proliferate in response to other hematopoietic growth factors such as GM-CSF, IL-3, and SCF. The cells were cultured in the various concentrations of rhTP0 for 3 days, followed by measurement of cell proliferation with the M'lT colorimetric method. Both M07E and TF-1 cells showed a dose-dependent proliferation in response to rhTPO over the range of 1 to 1 0 0 ng/mL, and almost maximal proliferation was observed at 20 ng/mL of rhTPO (Fig 2A) . Furthermore, when M07E and TF-l cells were cultured with rhTPO (20 ng/mL) in combination with rhIL-2 (50 ng/mL), rhIL-3 ( I O ng/mL), rhIL-6 (50 ng/mL), rhSCF (100 ng/mL), rhGM-CSF (IO ng/mL), or rhEPO ( I O U/mL), the growth factor-dependent proliferation of the cells was augmented by the addition of rhTPO ( Fig 2B) ; especially in TF-1 cells, rhTPO by itself has a minimal effect on proliferation of the cells, but the growth induced by rhIL-3, rhSCF, rhGM-CSF, or rhEPO was markedly augmented by rhTPO.
Effects of rhTP0 on proliferation of AML cells. We next examined the effects of rhTPO on in vitro proliferation of AML cells. Of 50 AML cases tested, 22 cases showed proliferative response to rhTPO at a concentration of 20 ng/mL (Tables 1 and 2 ). The proliferation of AML cells was induced in 19 of 26 c-mpl-positive cases, whereas rhTPO-induced proliferation was also observed in 3 of 24 AML cases in which c-mpl mRNA was barely detectable by Northern blot analysis ( Table 2) . With respect to FAB type, the proliferative response to rhTPO were observed not only in M7 (megakaryocytic) type but also in other types of AML. rhTPO induced proliferation of AML cells in 2 of 3 MO cases, 1 of 6 M1 cases, 5 of 9 M2 cases, 1 of 6 M3 cases, 2 of 8 M4 cases, 5 of 10 M5 cases, 2 of 4 M6 cases, and 4 of 4 M7 cases (Tables 1 and 2 ).
To further compare the effect of rhTP0 with that of other hematopoietic growth factors, AML cells were cultured with rhIL-3, rhIL-6, rhSCF, or rhGM-CSF, all of which had been shown to promote the growth of AML cells. As shown in Tables 1 and 2 , rhIL-3, rhIL-6, rhSCF, and rhGM-CSF induced proliferation of AML cells in 41, 22, 28, and 37 of 50 cases, respectively. The proliferative responses to those hematopoietic growth factors varied considerably from case to case, but in most of AML cases except MO and M7 types rhIL-3 or rhGM-CSF had a more potent activity in stimulating proliferation of AML cells than rhTPO. In addition, it was noted that proliferation of AML cells in the rhTPOresponsive cases could be promoted by one or more different hematopoietic factors ( Table l) . As was the case for hematopoietic cell lines, furthermore, rhTPO augmented the rhIL-3-, rhIL-6-, rhSCF-, or rhGM-CSF-induced proliferation of AML cells in a substantial fraction of cases.
DISCUSSION
During the past decade, a large number of hematopoietic growth factor receptors have been isolated and characterized at molecular and functional levels. Among these receptors, c-mpl has been thought to play a role in megakaryopoiesis based on its restricted expression on cells of megakaryocytic lineage as well as hematopoietic stem and also on the selective inhibition of megakaryocyte colony formation by the treatment with c-mpl antisense oligonucleotide.* Recent protein purification and gene cloning of the mpl ligand, TPO, provide direct evidence that the interaction between c-mpl and TPO is indispensable for normal megakaryopoiesis and thrombop~iesis?"~ However, the role of c-mpl For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From and TPO in abnormal growth of leukemia cells remains elusive.
In this study, we found that the c-mpl proto-oncogene was detectable by Northern blot analysis in 26 of 50 AML cases but not in any ALL cases tested. The amount of transcripts varied from case to case, and there was no significant correlation between the amount and expression of c-mpl and FAB classification. This observation was largely consistent with the previous findings by Vigon et a1,2R but in our study cmpl was found to be detectable in each subtype of AML and all of M7 cases showed positive signal for c-mpl transcript. When AML cells were cultured in the presence of rhTPO, proliferation of AML cells was stimulated with rhTPO alone in 19 of 26 AML cases that expressed c-mpl. Despite only a limited number of cases, furthermore, rhTPO induced proliferation of AML cells in which c-mpl mRNA was detectable by RT-PCR but not by Northern blot analysis. Proliferative response to rhTP0 was observed not only in all of M7 cases but also in a substantial fraction of AML cases other than M7. These results suggested that c-mpl may be functional in terms of supporting proliferation of various types of AML cases.
In addition to TPO, a number of hematopoietic growth factors such as IL-3, IL-6, SCF, and GM-CSF were shown to stimulate AML cells as well as megakaryocytes and were suggested to be involved in the growth of myeloid leukemia
As compared with rhTPO, proliferation of AML cells was stimulated with significantly higher frequency by rhIL-3 or rhGM-CSF, with slightly higher frequency by rhSCF, and with similar frequency by rhIL-6. The proliferative responses of AML cells to each of these hematopoietic growth factors were neither correlated with c-mpl expression nor with TPO responsiveness. However, the rhIL-3-, rhGM-CSF-, rhSCF-, and rhIL-6-induced proliferation of AML cells was augmented by the addition of rhTPO in a substantial fraction of AML cases, including some cases that did not show proliferative response to rhTPO alone. These results suggested that TPO might contribute, at least in part, to abnormal growth of AML cells, especially in combination with other hematopoietic growth factors.
Molecular cloning of human c-mpl have identified two types of cDNAs encoding the P and K forms of c-mpl that have sequence homology to members of hematopoietin receptor superfamily? In AML cells, both forms of c-mpl mRNA were found to be coexpressed in each case, but the expression level of K-form c-mpl was much lesser than that of P-form c-mpl. These results suggested that P-form c-mpl may play a major role in the TPO-induced proliferation of AML cells, although functional role of each form of c-mpl are not characterized at this time. The experiments are currently in progress to understand the mechanisms by which TPO mediates proliferative signals into AML cells.
It has recently been shown that c-mpl-deficient mice generated by gene targeting had a striking decrease in the numbers of platelets and megakaryocytes but had normal amounts of other hematopoietic cell types.38 Furthermore, daily infusion of TPO into mice has been shown to induce a dramatical increase in the counts of platelets, megakaryocytes, and megakaryocyte-progenitor cells, but to have only minimal effects on other cell types.'"." These data indicated For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From that action of TPO will be restricted to megakaryocytes and platelets. However, in the case of AML, TPO had a proliferative potential on a wide variety of AML cases other than cases of megakaryocytic (M7) type. In addition, a detailed understanding of TPO effect on other cell types, including very immature hematopoietic stem cells, awaits further studies. A clear and decisive information concerning the effect of TPO on various types of normal and abnormal hematopoietic cells will be necessary to construct novel therapeutic strategies for the treatment of thrombocytepenic patients with TPO.
